Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life
PurposeBladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate ge...
Saved in:
| Published in | BMJ open Vol. 13; no. 12; p. e075942 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
British Medical Journal Publishing Group
20.12.2023
BMJ Publishing Group LTD BMJ Publishing Group |
| Series | Cohort profile |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2044-6055 2044-6055 |
| DOI | 10.1136/bmjopen-2023-075942 |
Cover
| Abstract | PurposeBladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.ParticipantsCOBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up.Findings to dateWe describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy.Future plansCOBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making. |
|---|---|
| AbstractList | PurposeBladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.ParticipantsCOBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up.Findings to dateWe describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy.Future plansCOBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making. Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.PURPOSEBladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.COBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up.PARTICIPANTSCOBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up.We describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy.FINDINGS TO DATEWe describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy.COBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making.FUTURE PLANSCOBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making. Purpose Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.Participants COBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up.Findings to date We describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy.Future plans COBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making. Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting. COBLAnCE ( hort to study dder anc r) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up. We describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy. COBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making. Purpose Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting. Participants COBLAnCE ( CO hort to study BLA dder C anc E r) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up. Findings to date We describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy. Future plans COBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making. |
| Author | Neuzillet, Yann Mangin, Anthony Villers, Arnauld Descotes, Jean-Luc Sirab, Nanor Ghaleh, Bijan Fraslin, Aldéric Guy, Laurent Eschwege, Pascal Mariani, Odette Coloby, Patrick Benhamou, Simone Radvanyi, François Lacoste, Jean Loison, Guillaume Allory, Yves Droupy, Stéphane Groussard, Karine Lebret, Thierry Méjean, Arnaud Bonastre, Julia Vordos, Dimitri Lacoste, Jacques Schneider, Marc Blanché, Hélène Rebillard, Xavier |
| AuthorAffiliation | 13 Urology , CHU Grenoble Alpes , Grenoble , France 17 Biological Resources Center , Curie Institute Hospital Group , Paris , France 4 Urology , Clinique Beau Soleil , Montpellier , France 3 Urology , Centre Hospitalier Universitaire de Nimes , Nimes , France 16 Fondation Jean Dausset , Paris , Île-de-France , France 14 Urology , CHU de Nancy Hôpital de Brabois Adultes , Vandoeuvre-les-Nancy , France 6 Urology , University Hospital Centre Gabriel Montpied , Clermont-Ferrand , France 20 U1018 , INSERM , Villejuif , France 15 Urology , la Croix du Sud Clinic , Quint Fonsegrives , France 9 Urology , University Hospital Center René Dubos , Cergy-Pontoise , France 5 Clinical Investigation Center 1430 , INSERM , Créteil , France 1 Urology , Hôpital Foch , Suresnes , France 21 UMR444 , CNRS , Paris , France 8 Urology , Hopitaux Civils de Colmar , Colmar , France 22 Patholgy , Curie Institute Saint Cloud , Saint-Cloud , France 12 Urology , Atlantis Clinic , Saint-Herblain , France 11 Urology , Hopital Europee |
| AuthorAffiliation_xml | – name: 8 Urology , Hopitaux Civils de Colmar , Colmar , France – name: 12 Urology , Atlantis Clinic , Saint-Herblain , France – name: 22 Patholgy , Curie Institute Saint Cloud , Saint-Cloud , France – name: 5 Clinical Investigation Center 1430 , INSERM , Créteil , France – name: 16 Fondation Jean Dausset , Paris , Île-de-France , France – name: 9 Urology , University Hospital Center René Dubos , Cergy-Pontoise , France – name: 1 Urology , Hôpital Foch , Suresnes , France – name: 20 U1018 , INSERM , Villejuif , France – name: 21 UMR444 , CNRS , Paris , France – name: 4 Urology , Clinique Beau Soleil , Montpellier , France – name: 7 Urology , Claude Huriez Hospital , Lille , France – name: 13 Urology , CHU Grenoble Alpes , Grenoble , France – name: 11 Urology , Hopital Europeen Georges Pompidou , Paris , France – name: 3 Urology , Centre Hospitalier Universitaire de Nimes , Nimes , France – name: 15 Urology , la Croix du Sud Clinic , Quint Fonsegrives , France – name: 18 Biological Resources Platform , Hôpital Henri Mondor , Creteil , France – name: 19 Pathology , Curie Institute , Paris , France – name: 10 Urology , Private Hospital of Provence , Aix-en-Provence , France – name: 14 Urology , CHU de Nancy Hôpital de Brabois Adultes , Vandoeuvre-les-Nancy , France – name: 2 Biostatistics and Epidemiology , Gustave Roussy , Villejuif , France – name: 6 Urology , University Hospital Centre Gabriel Montpied , Clermont-Ferrand , France – name: 17 Biological Resources Center , Curie Institute Hospital Group , Paris , France |
| Author_xml | – sequence: 1 givenname: Thierry surname: Lebret fullname: Lebret, Thierry organization: Urology, Hôpital Foch, Suresnes, France – sequence: 2 givenname: Julia surname: Bonastre fullname: Bonastre, Julia organization: Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France – sequence: 3 givenname: Aldéric surname: Fraslin fullname: Fraslin, Aldéric organization: Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France – sequence: 4 givenname: Yann surname: Neuzillet fullname: Neuzillet, Yann organization: Urology, Hôpital Foch, Suresnes, France – sequence: 5 givenname: Stéphane surname: Droupy fullname: Droupy, Stéphane organization: Urology, Centre Hospitalier Universitaire de Nimes, Nimes, France – sequence: 6 givenname: Xavier surname: Rebillard fullname: Rebillard, Xavier organization: Urology, Clinique Beau Soleil, Montpellier, France – sequence: 7 givenname: Dimitri surname: Vordos fullname: Vordos, Dimitri organization: Clinical Investigation Center 1430, INSERM, Créteil, France – sequence: 8 givenname: Laurent surname: Guy fullname: Guy, Laurent organization: Urology, University Hospital Centre Gabriel Montpied, Clermont-Ferrand, France – sequence: 9 givenname: Arnauld surname: Villers fullname: Villers, Arnauld organization: Urology, Claude Huriez Hospital, Lille, France – sequence: 10 givenname: Marc surname: Schneider fullname: Schneider, Marc organization: Urology, Hopitaux Civils de Colmar, Colmar, France – sequence: 11 givenname: Patrick surname: Coloby fullname: Coloby, Patrick organization: Urology, University Hospital Center René Dubos, Cergy-Pontoise, France – sequence: 12 givenname: Jean surname: Lacoste fullname: Lacoste, Jean organization: Urology, Private Hospital of Provence, Aix-en-Provence, France – sequence: 13 givenname: Arnaud surname: Méjean fullname: Méjean, Arnaud organization: Urology, Hopital Europeen Georges Pompidou, Paris, France – sequence: 14 givenname: Jacques surname: Lacoste fullname: Lacoste, Jacques organization: Urology, Atlantis Clinic, Saint-Herblain, France – sequence: 15 givenname: Jean-Luc surname: Descotes fullname: Descotes, Jean-Luc organization: Urology, CHU Grenoble Alpes, Grenoble, France – sequence: 16 givenname: Pascal surname: Eschwege fullname: Eschwege, Pascal organization: Urology, CHU de Nancy Hôpital de Brabois Adultes, Vandoeuvre-les-Nancy, France – sequence: 17 givenname: Guillaume surname: Loison fullname: Loison, Guillaume organization: Urology, la Croix du Sud Clinic, Quint Fonsegrives, France – sequence: 18 givenname: Hélène surname: Blanché fullname: Blanché, Hélène organization: Fondation Jean Dausset, Paris, Île-de-France, France – sequence: 19 givenname: Odette surname: Mariani fullname: Mariani, Odette organization: Biological Resources Center, Curie Institute Hospital Group, Paris, France – sequence: 20 givenname: Bijan surname: Ghaleh fullname: Ghaleh, Bijan organization: Biological Resources Platform, Hôpital Henri Mondor, Creteil, France – sequence: 21 givenname: Anthony surname: Mangin fullname: Mangin, Anthony organization: Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France – sequence: 22 givenname: Nanor surname: Sirab fullname: Sirab, Nanor organization: Pathology, Curie Institute, Paris, France – sequence: 23 givenname: Karine surname: Groussard fullname: Groussard, Karine organization: U1018, INSERM, Villejuif, France – sequence: 24 givenname: François surname: Radvanyi fullname: Radvanyi, François organization: UMR444, CNRS, Paris, France – sequence: 25 givenname: Yves surname: Allory fullname: Allory, Yves organization: Patholgy, Curie Institute Saint Cloud, Saint-Cloud, France – sequence: 26 givenname: Simone orcidid: 0000-0003-1162-9165 surname: Benhamou fullname: Benhamou, Simone email: simone.benhamou@inserm.fr organization: U1018, INSERM, Villejuif, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38128940$$D View this record in MEDLINE/PubMed https://hal.science/hal-04381735$$DView record in HAL |
| BookMark | eNqFks1u1DAUhSNUREvpEyAhS2xAItR27Px0g8qopZVG6gbWlmPfzHiUsae2M2hekafCaYbSzgKycXzvd46dm_M6O7LOQpa9JfgzIUV53q5XbgM2p5gWOa54w-iL7IRixvISc3705P04OwthhdPDeMM5fZUdFzWhdcPwSfZr5pbOR7TxrjM9XKDZ3df5pZ1dXSCJrj1YtRx7YQMqmi0gNeHRoRAHvRt7C-tCNApJq9MWtJnITqrofEDGoraXWoNHSlqVlhFMBguw4GUE5EH2-U_ne420jBI5i2KqxTXYdDEZI3gbPiUsuMErQEOAB4_7QfYm7pDrUG86eJO97GQf4Gy_nmY_rq--z27y-d2329nlPG95xWLeKaigalulaoC26nRBsFYlUMW6GggvKK1I1fASA1FtyTGrOWVFU9OSFxWjxWl2O_lqJ1di481a-p1w0oiHgvMLIX0aSA-iromSkivNJLCKla3SrSaclmXBG8l48voyeW2Gdg1apS_2sn9m-rxjzVIs3FYQXLEG4zo5fJwclge6m8u5GGuYpb9dFXxLEvthf5p39wOEKNYmKOh7acENQdAmxYWyqmkS-v4AXaXh2zTXkapTljAtE_Xu6fUfz_-TrwQUE6BShoKH7hEhWIxBFvsgizHIYgpyUjUHKmWijMaNMzD9f7TnkzY1_975X4rfF2IMJQ |
| CitedBy_id | crossref_primary_10_1016_j_euros_2024_09_006 crossref_primary_10_3390_cancers16213653 crossref_primary_10_3390_ijerph21121633 crossref_primary_10_3390_cancers15174218 |
| Cites_doi | 10.1016/j.juro.2016.12.090 10.1016/j.eururo.2012.10.039 10.1158/1940-6207.CAPR-17-0084 10.1002/ijc.31214 10.1056/NEJMc2110897 10.1056/NEJMoa2002788 10.1136/bmjopen-2019-030396 10.1007/s10552-019-1130-8 10.21037/tau.2018.08.20 10.1016/S0140-6736(99)02292-8 10.3322/caac.21492 10.1002/ijc.31937 10.1001/jama.2020.17598 10.1056/NEJMoa022148 10.1056/NEJMoa1613683 10.1016/j.eururo.2018.09.001 10.1158/1055-9965.EPI-06-0021 10.1111/j.1464-410X.2009.08849.x 10.1016/j.euo.2020.06.009 10.1016/j.eururo.2020.03.055 10.1186/s12885-016-2877-x 10.1080/14737140.2018.1451748 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ K9- K9. KB0 M0R M0S M1P M2M NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1136/bmjopen-2023-075942 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central BMJ Journals ProQuest One Community College ProQuest Central Korea ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Psychology Database ProQuest Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition BMJ Journals ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2044-6055 |
| ExternalDocumentID | oai_doaj_org_article_881caa5cd4ae4746bcdbd15266359a45 PMC10749008 oai_HAL_hal_04381735v1 38128940 10_1136_bmjopen_2023_075942 bmjopen |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: Agence Nationale de la Recherche France 2030 grantid: ANR-10-COHO-0007 – fundername: Ligue Contre le Cancer grantid: EP 2011 funderid: http://dx.doi.org/10.13039/501100004099 – fundername: ; grantid: ANR-10-COHO-0007 – fundername: ; grantid: EP 2011 |
| GroupedDBID | --- 4.4 53G 5VS 7RV 7X7 7~R 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BKNYI BPHCQ BTFSW BTHHO CCPQU DIK DWQXO EBS FYUFA GNUQQ GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ K9- KQ8 M0R M1P M2M M48 M~E NAPCQ O9- OK1 PGMZT PHGZT PIMPY PQQKQ PROAC PSQYO PSYQQ RHI RMJ RPM UKHRP AAYXX ADRAZ BVXVI CITATION EJD PHGZM 3V. CGR CUY CVF ECM EIF NPM RHF 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 PUEGO 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-b574t-fce7e7bbcc8eeb7fd310dc6e2c4f8e153227179560e1cb6504852439826537423 |
| IEDL.DBID | M48 |
| ISSN | 2044-6055 |
| IngestDate | Wed Aug 27 01:28:21 EDT 2025 Thu Aug 21 18:37:32 EDT 2025 Fri Sep 12 12:46:56 EDT 2025 Fri Sep 05 13:56:47 EDT 2025 Fri Jul 25 09:36:15 EDT 2025 Wed Feb 19 02:08:38 EST 2025 Thu Apr 24 23:06:21 EDT 2025 Tue Jul 01 04:20:21 EDT 2025 Mon May 05 14:20:41 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Urological tumours EPIDEMIOLOGY Prognosis |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. Attribution: http://creativecommons.org/licenses/by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b574t-fce7e7bbcc8eeb7fd310dc6e2c4f8e153227179560e1cb6504852439826537423 |
| Notes | Cohort profile ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 PMCID: PMC10749008 |
| ORCID | 0000-0003-1162-9165 0000-0003-2235-0012 0000-0001-5853-8047 0000-0002-5696-6424 0000-0002-6453-2917 0000-0002-3701-5682 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1136/bmjopen-2023-075942 |
| PMID | 38128940 |
| PQID | 2908004026 |
| PQPubID | 2040975 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_881caa5cd4ae4746bcdbd15266359a45 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10749008 hal_primary_oai_HAL_hal_04381735v1 proquest_miscellaneous_2905524799 proquest_journals_2908004026 pubmed_primary_38128940 crossref_primary_10_1136_bmjopen_2023_075942 crossref_citationtrail_10_1136_bmjopen_2023_075942 bmj_journals_10_1136_bmjopen_2023_075942 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-20 |
| PublicationDateYYYYMMDD | 2023-12-20 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationSeriesTitle | Cohort profile |
| PublicationTitle | BMJ open |
| PublicationTitleAbbrev | BMJ Open |
| PublicationTitleAlternate | BMJ Open |
| PublicationYear | 2023 |
| Publisher | British Medical Journal Publishing Group BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: British Medical Journal Publishing Group – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Lenis, Lec, Chamie (R3) 2020; 324 Ferlay, Colombet, Soerjomataram (R1) 2019; 144 de Goeij, Westhoff, Witjes (R5) 2019; 9 Witjes, Bruins, Cathomas (R20) 2021; 79 Rouanne, Bajorin, Hannan (R23) 2020; 3 Zamboni, Baumeister, Mattei (R17) 2019; 8 Oddens, Brausi, Sylvester (R18) 2013; 63 Grossman, Natale, Tangen (R22) 2003; 349 Bajorin, Collette, Galsky (R24) 2021; 385 Bray, Ferlay, Soerjomataram (R15) 2018; 68 (R21) 1999; 354 Powles, Park, Voog (R25) 2020; 383 Benhamou, Bonastre, Groussard (R9) 2016; 16 Kwan, Kushi, Danforth (R7) 2019; 30 Zeegers, Bryan, Langford (R6) 2010; 105 Cumberbatch, Jubber, Black (R2) 2018; 74 Samanic, Kogevinas, Dosemeci (R4) 2006; 15 Chou, Selph, Buckley (R19) 2017; 197 Westhoff, Wu, Kiemeney (R8) 2018; 142 Bellmunt, de Wit, Vaughn (R26) 2017; 376 Oosterlinck, Decaestecker (R16) 2018; 18 Malhotra, Borron, Freedman (R11) 2017; 10 Chou (2023122022451187000_13.12.e075942.19) 2017; 197 Westhoff (2023122022451187000_13.12.e075942.8) 2018; 142 2023122022451187000_13.12.e075942.22 2023122022451187000_13.12.e075942.21 2023122022451187000_13.12.e075942.20 2023122022451187000_13.12.e075942.1 2023122022451187000_13.12.e075942.26 Kwan (2023122022451187000_13.12.e075942.7) 2019; 30 2023122022451187000_13.12.e075942.25 2023122022451187000_13.12.e075942.5 2023122022451187000_13.12.e075942.4 2023122022451187000_13.12.e075942.3 2023122022451187000_13.12.e075942.2 2023122022451187000_13.12.e075942.9 2023122022451187000_13.12.e075942.6 Zamboni (2023122022451187000_13.12.e075942.17) 2019; 8 2023122022451187000_13.12.e075942.12 2023122022451187000_13.12.e075942.11 2023122022451187000_13.12.e075942.10 2023122022451187000_13.12.e075942.15 Rouanne (2023122022451187000_13.12.e075942.23) 2020; 3 2023122022451187000_13.12.e075942.14 2023122022451187000_13.12.e075942.13 Bajorin (2023122022451187000_13.12.e075942.24) 2021; 385 Oosterlinck (2023122022451187000_13.12.e075942.16) 2018; 18 2023122022451187000_13.12.e075942.18 |
| References_xml | – volume: 197 start-page: 1189 year: 2017 ident: R19 article-title: Intravesical therapy for the treatment of non muscle invasive bladder cancer: a systemic review and meta-analysis publication-title: J Urol doi: 10.1016/j.juro.2016.12.090 – volume: 63 start-page: 462 year: 2013 ident: R18 article-title: Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in Intermediate- and high-risk TA, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance publication-title: Eur Urol doi: 10.1016/j.eururo.2012.10.039 – volume: 10 start-page: 704 year: 2017 ident: R11 article-title: Association between cigar or pipe smoking and cancer risk in men: a pooled analysis of five cohort studies publication-title: Cancer Prev Res (Phila) doi: 10.1158/1940-6207.CAPR-17-0084 – volume: 142 start-page: 1797 year: 2018 ident: R8 article-title: Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer publication-title: Int J Cancer doi: 10.1002/ijc.31214 – volume: 385 start-page: 957 year: 2021 ident: R24 article-title: Adjuvant nivolumab versus placebo in muscle_invasive urothelial carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMc2110897 – volume: 383 start-page: 1218 year: 2020 ident: R25 article-title: Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa2002788 – volume: 9 year: 2019 ident: R5 article-title: The urolife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life publication-title: BMJ Open doi: 10.1136/bmjopen-2019-030396 – volume: 30 start-page: 187 year: 2019 ident: R7 article-title: The be-well study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer publication-title: Cancer Causes Control doi: 10.1007/s10552-019-1130-8 – volume: 8 start-page: 76 year: 2019 ident: R17 article-title: Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication? publication-title: Transl Androl Urol doi: 10.21037/tau.2018.08.20 – volume: 354 start-page: 533 year: 1999 ident: R21 article-title: Neoadjuvant cisplatin, methotrexate, and Vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists publication-title: Lancet doi: 10.1016/S0140-6736(99)02292-8 – volume: 68 start-page: 394 year: 2018 ident: R15 article-title: Global cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 144 start-page: 1941 year: 2019 ident: R1 article-title: Estimating the global incidence and mortality in 2018: GLOBOCAN sources and methods publication-title: Int J Cancer doi: 10.1002/ijc.31937 – volume: 324 start-page: 1980 year: 2020 ident: R3 article-title: Bladder cancer: a review publication-title: JAMA doi: 10.1001/jama.2020.17598 – volume: 349 start-page: 859 year: 2003 ident: R22 article-title: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa022148 – volume: 376 start-page: 1015 year: 2017 ident: R26 article-title: Pembrolizumab as second-line therapy for advanced urothelial carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1613683 – volume: 74 start-page: 784 year: 2018 ident: R2 article-title: Epidemiology of bladder cancer: a systemic review and contemporary update of risk factors in 2018 publication-title: Eur Urol doi: 10.1016/j.eururo.2018.09.001 – volume: 15 start-page: 1348 year: 2006 ident: R4 article-title: Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-06-0021 – volume: 105 start-page: 784 year: 2010 ident: R6 article-title: The West Midlands bladder cancer prognosis programme: rationale and design publication-title: BJU Int doi: 10.1111/j.1464-410X.2009.08849.x – volume: 3 start-page: 728 year: 2020 ident: R23 article-title: Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2020.06.009 – volume: 79 start-page: 82 year: 2021 ident: R20 article-title: European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines publication-title: Eur Urol doi: 10.1016/j.eururo.2020.03.055 – volume: 16 year: 2016 ident: R9 article-title: A prospective multicenter study on bladder cancer: the coblance cohort publication-title: BMC Cancer doi: 10.1186/s12885-016-2877-x – volume: 18 start-page: 437 year: 2018 ident: R16 article-title: Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2018.1451748 – ident: 2023122022451187000_13.12.e075942.2 doi: 10.1016/j.eururo.2018.09.001 – ident: 2023122022451187000_13.12.e075942.4 doi: 10.1158/1055-9965.EPI-06-0021 – ident: 2023122022451187000_13.12.e075942.5 doi: 10.1136/bmjopen-2019-030396 – ident: 2023122022451187000_13.12.e075942.10 – ident: 2023122022451187000_13.12.e075942.22 doi: 10.1056/NEJMoa022148 – ident: 2023122022451187000_13.12.e075942.21 doi: 10.1016/S0140-6736(99)02292-8 – ident: 2023122022451187000_13.12.e075942.20 doi: 10.1016/j.eururo.2020.03.055 – volume: 385 start-page: 957 year: 2021 ident: 2023122022451187000_13.12.e075942.24 article-title: Adjuvant nivolumab versus placebo in muscle_invasive urothelial carcinoma publication-title: N Engl J Med – ident: 2023122022451187000_13.12.e075942.3 doi: 10.1001/jama.2020.17598 – volume: 197 start-page: 1189 year: 2017 ident: 2023122022451187000_13.12.e075942.19 article-title: Intravesical therapy for the treatment of non muscle invasive bladder cancer: a systemic review and meta-analysis publication-title: J Urol doi: 10.1016/j.juro.2016.12.090 – volume: 8 start-page: 76 year: 2019 ident: 2023122022451187000_13.12.e075942.17 article-title: Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication? publication-title: Transl Androl Urol doi: 10.21037/tau.2018.08.20 – ident: 2023122022451187000_13.12.e075942.13 – ident: 2023122022451187000_13.12.e075942.6 doi: 10.1111/j.1464-410X.2009.08849.x – volume: 18 start-page: 437 year: 2018 ident: 2023122022451187000_13.12.e075942.16 article-title: Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2018.1451748 – ident: 2023122022451187000_13.12.e075942.25 doi: 10.1056/NEJMoa2002788 – volume: 30 start-page: 187 year: 2019 ident: 2023122022451187000_13.12.e075942.7 article-title: The be-well study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer publication-title: Cancer Causes Control doi: 10.1007/s10552-019-1130-8 – ident: 2023122022451187000_13.12.e075942.26 doi: 10.1056/NEJMoa1613683 – ident: 2023122022451187000_13.12.e075942.1 doi: 10.1002/ijc.31937 – ident: 2023122022451187000_13.12.e075942.15 doi: 10.3322/caac.21492 – ident: 2023122022451187000_13.12.e075942.9 doi: 10.1186/s12885-016-2877-x – volume: 3 start-page: 728 year: 2020 ident: 2023122022451187000_13.12.e075942.23 article-title: Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2020.06.009 – ident: 2023122022451187000_13.12.e075942.12 – ident: 2023122022451187000_13.12.e075942.14 – ident: 2023122022451187000_13.12.e075942.11 doi: 10.1158/1940-6207.CAPR-17-0084 – ident: 2023122022451187000_13.12.e075942.18 doi: 10.1016/j.eururo.2012.10.039 – volume: 142 start-page: 1797 year: 2018 ident: 2023122022451187000_13.12.e075942.8 article-title: Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer publication-title: Int J Cancer doi: 10.1002/ijc.31214 |
| SSID | ssj0000459552 |
| Score | 2.3922849 |
| Snippet | PurposeBladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients... Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in... Purpose Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients... |
| SourceID | doaj pubmedcentral hal proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e075942 |
| SubjectTerms | Biomarkers Bladder cancer Cancer Chronic illnesses Cystectomy Disease Epidemiology Female Humans Life Sciences Lifestyles Male Medical prognosis Non-Muscle Invasive Bladder Neoplasms Patients Prognosis Prospective Studies Quality of Life Recruitment Smoking Tobacco Urinary Bladder Neoplasms - pathology Urine Urological surgery Urological tumours |
| SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LbxMxEB61Rap6QbzZUpBBHDh0m6zX--otjRpFqMCllcpptfbaTVDwVsmmEn-RX8WM9wELUsUpij07yWrG9jf2-BuA93FalqXRxqcqPr7QJvCzMhv7MgoTE2sE6IXL8v0cz6_Ex-voegd4dxdGfv9GZaNO8LO50UAcTbYeBeEo4CONC1wm-AltTe_CA-LiIr787Otlv6-CECWLXKEdPhbCR7QetWRDQRh36n0qGu43yg5gH1ctjDto_2MXBQYrlCPyx_YFpUn-i0H_TqX8Y22aPYKHLahkk8YLHsOOtk9g_1N7bP4Ufk6rBcJs1hboPmXTL2cXEzs9P2UFm9F9vwX1dbcumWrE64o59lnqo3w81M4KW-JX0uwk23I9bGmZXNEktmaK_GjtBFHBjaO1rjVDcLryHT8ro6xUVlnWJ7mzW8fyaTfHKNYcJ7DtRjsdza3PH6wybLU0-hlczc4vp3O_LeKA5k5E7RulE51IqVSqtUxMiXiyVLHmSphU43zLOUaUFKXpQEnEiyKNOKIkDHvQXRDsPYc9W1n9EliaoKHCEGcUo3HqSQuZFEVk-DhOJcKa0IMPaL68HYSb3MU3YZy3Rs_J6HljdA94Z-NctWToVJNjdf9Dx_1Dtw0XyP3iZ-Q8vSgRebuGan2Tt_NCnqaBwpdQpSi0SEQsVSlLxFQEBLNCRB68Q9cb6JhPLnJqc-xsSRjdBR4cdZ75--15RsGAwBjbg7d9N04edCJUWF1tnQyOFZFkmQcvGkfuf6obFB6kAxcf_Jdhj10uHEE5JflmaKDD_zfIKzhwYzLgODaPYK9eb_VrhHu1fOPG9y8HGk_P priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgD4gL4k3YBRnEgcNGm4cT23vrVltVaIELK-0til-0qCSrNl2Jv8ivYsZxQwPScuFYezJNMuPxN_LkG0LelcIY46yLsYtPzKxLY2lkEqsi5660ANBrX-X7qZxfsg9XxdVeqy-sCevpgfsXdyJEquu60IbVlnFWKm2UgU0Hd0pZM89emshkL5nyMZgVsiiyQDOU5uWJ-v4N-1HF2C48hn1SYnP2uzA62pA8bz-ML7Aq8m_I-Wfl5N5WNHtIHgQMSSf9vT8id2zzmNz7GE7Jn5Cf03YBqJqGftyndPr57GLSTM9PaU1n-HnfAud2H1lS3Yt3LfVksziH5XegndaNgZ-o2UuG7jx02VC1wpi1phrdZu0FQcFXz2LdWQpYdBV7OlaKRai0behQ006vPalnszkGsf70gG431uvoP_L8QVtHV0tnn5LL2fmX6TwOPRvAupx1sdOWW66U1sJaxZ0B-Gh0aTPNnLAQXrMMEkhMymyqFcBDJooMQBFkOeAdgO2ekYOmbewLQgUHNJHnEECchUgjasXBEVyWlEIBiskj8h7MV4U1t6l8OpOXVbB0hZauektHJNvZuNKB-xxbcKxuv-h4uOi6p_64XfwMnWcQRd5uPwDeXAVvrv7lzRF5C6430jGfXFQ45snYeF7cpBE52nnm76fPJGJ_Bil1RN4M0xAr8ACobmy79TKwKBiXMiLPe0ce_gqUQ-7NkoiIkYuP7mU80ywXno8ca3olGOjl_3gDh-S-X6JpBkv1iBx06619BbivU6_9Ev8FTIBXYQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYkBAviG8yBjKIBx5mrUmc2NkL6qpVFRrwwqS-RfHX2qkkpR-T-Bf5q7hz3IyA1Mfal2ui-_Dv7PMdIR9yaYxx1jHs4sO4dTErTDFgKkuFyy0A9Mpn-X7NJ1f88zSbhg23dUir3PlE76hNo3GP_DQpENtAtJN_Wv5k2DUKT1dDC40Dcj8GqIJaLaai22MBuFJkWRKKDcVpfqp-3GBXKoZNwxmslgW2aD-A0d6y5Kv3w_gMcyP_B57_5k_-tSCNH5NHAUnSYSv6J-SerZ-SB1_CWfkz8nvUzABb09CV-4yOvp1fDuvRxRmt6Bgv-c1wbnfVkuqWfNNQX3IW5zAJD7jTqjbwEzl7ytCjh85rqhbouVZUo_KsPCEwuPa1rDeWAiJdMF-UlWIqKm1q2mW206Uv7VmvT4CsPUOg27X1PNqrnr9o4-hi7uxzcjW--D6asNC5AWQs-IY5bYUVSmktrVXCGQCRRuc20dxJC042SSCMxNDMxloBSOQySwAaQawDOgII7wU5rJvaviJUCsAUaQpuxFnwN7JSoqoylwxyqQDLpBH5COIrg-WtSx_UpHkZJF2ipMtW0hFJdjIudaiAjo04FvsfOukeWrYFQPaTn6PydKRYvdsPNKvrMjiDUspYw0dowyvLBc-VNsoAkEL0V1Q8i8h7UL0ej8nwssQxX5JNpNltHJHjnWbeff2dlUTkXTcNHgOPgaraNltPA0bBRVFE5GWryN1fAXOIwPkgIrKn4r136c_U85mvSo6ZvQUI6Gj_e70mD73xxQkY4TE53Ky29g3guo166433D4-6Tls priority: 102 providerName: ProQuest |
| Title | Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life |
| URI | https://bmjopen.bmj.com/content/13/12/e075942.full https://www.ncbi.nlm.nih.gov/pubmed/38128940 https://www.proquest.com/docview/2908004026 https://www.proquest.com/docview/2905524799 https://hal.science/hal-04381735 https://pubmed.ncbi.nlm.nih.gov/PMC10749008 https://doaj.org/article/881caa5cd4ae4746bcdbd15266359a45 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_tQ5r2gvheYFQG8cDDAkvixMkkhNqqpULrQGhF5SmKHWctKsnoB2L_In8Vd45TKB974CVV7LNT587n38XnO4CnUZzneaELl7L4uFwXnpvkybErw0AUkUaAnhkv37NoMOJvxuF4C5qsqPYFLv5q2lE-qdF89vzbl6tXOOFf2owkL-TnT1TlUiZwF5fAhKNO3sWlyScxH1q8b1QzD5Mw9G30oX-03Yc9XMbQEKEPIttIsLFkmcj-WD4hv8k_QenvvpW_LFb9m3DDokzWrsXiFmzp8jbsDe0--h343q0mOGRmM3afsO7bzmm77PZOWMb6dABwQnXNMUymavJlxUw4WqojBz3snWVljrfUs6G0-XvYtGRyRlptzhQJ1twQYgcXJs71UjNEqzPXBGxl5KbKqpKtvd7ZpQn7WS6OkKzeX2CrhTZ91MdAr1hVsNm00Hdh1O-ddweuzeqA_Bd86RZKCy2kVCrWWooiR4CZq0j7ihexRgXs-2hiktmmPSURQPI49BE2oR2E8oPo7x7slFWpD4DFAhkVBKhiCo26KM6kyLKw8I-jWCLOCRx4huxLG6FKjcETRKllekpMT2umO-A3PE6VjY5OSTpm1zc6Wje6rIODXE_eIeFZk1Jkb1NQzS9SqyjSOPYUDkLlPNNc8EiqXOYIsggZJhkPHXiCorfRx6B9mlKZCdcmgvCr58BhI5k_R-8nZB1wNLodeLyuRm1CW0RZqauVocH5wUWSOHC_FuT1o5pJ4UC8IeIb_2WzppxOTMRy8vpNkEEP_r_pQ9g3c9Tzca4ews5yvtKPEA8uZQu2xVjgNfl43oLddnc4_IC_nd7Zu_ct840Fr6_HXsvogh9HSWeh |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGJgEviDuBAQaBxMOiNY5zmzShtrTqWFcQ2qS9ZfEla1FJSi-g_Tl-AL-KcxwnoyDtbY-1T1xH5-LP8fH5CHkTxkqpXOcusvi4XOeem6ik5YrAj_JQA0DPTJbvKByc8I-nwekG-VXfhcG0yjommkCtSonfyHdZgtgGdjvh-9l3F1mj8HS1ptDILLWC2jclxuzFjkN98RO2cIv9gw-g77eM9XvH3YFrWQZgPhFfurnUkY6EkDLWWkS5AsCjZKiZ5HmsISAwBlse3EZoTwoANDwOGCzjgMvhfTgWPoAlYAtghw9etdXpjT5_ab7yAGBKgoDZckeeH-6Kb1-RF8tF2nIX1usESeJvQOvawmj4A6B9jNmZ_0PffzM4_1oS-3fJHYtlabsyvntkQxf3yc0je1r_gPzulmNA99Tygu_R7qfOsF10e3s0o328ZjjGvvqyJ5WV-LKkpugt9mEaIIxOs0LBTxzZSFqWIDopqJhi7JxTieY7N4IwwLmppr3UFDDx1DVlYSkmw9KyoE1uPZ2Z4qLFYgfEqlMMulpoM0Z12fSCljmdTnL9kJxci1Yfkc2iLPQTQuMIUI3vQyDLNUS8OBNRlgU5a4WxADTlO-QdqC-1vr9IzbbKD1Or6RQ1nVaadgirdZxKW4MdqUCmVz-00zw0q0qQXC3eQeNpRLF-uGko5-epDUdpHHsSXkIqnmke8VBIJRRAOcSfScYDh7wG01sbY9AepthmisJFfvDDc8h2bZmXb3_ppw551XRDzMKDqKzQ5crIgFPwKEkc8rgy5OavYHAWJ7zlkHjNxNfmst5TTMamLjrmFiegoKdXz-sluTU4Phqmw4PR4TNy2ziix8Aht8nmcr7SzwFlLsUL68qUnF139PgDI7yQ-Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkCZeEN8EBhgEEg-L2jhOnExCqOtWdawMHpjUtyx27LWoJKVNQfvX-BP4q7hzPkZB6tsea1-uju7Dv4vPd4S8DqMsy4w2Lnbxcbk2nhtncdeVgS9MqAGgpzbL9zQcnvEP42C8RX41d2EwrbLxidZRZ4XCb-QdFiO2gWgn7Jg6LeLz4eD9_LuLHaTwpLVpp1GpyIm-_Anh2_Ld8SHI-g1jg6Mv_aFbdxiAtQheukZpoYWUSkVaS2EyADuZCjVT3EQanAFjEO5gCKE9JQHM8ChgsIUDJod34Vj0ANz_TeHDGNiSGIv2-w5ApTgIWF3oyPPDjvz2FTtiudiw3IWdOsb28DdgdG1LtJ0DYHyCeZn_g95_czf_2gwHd8jtGsXSXqV2d8mWzu-RnY_1Of198rtfTADX07oj-D7tfzoY9fL-0T5N6QAvGE5wrrnmSVVFXhbUlrvFOUwABO40zTP4iZwtZd0fiE5zKmfoNRdUoeIuLCEwuLB1tEtNAQ3PXFsQlmIaLC1y2mbV07ktK5ov94CsOr-gq6W2PKprppe0MHQ2NfoBObsWmT4k23mR68eERgLwjO-DCzMafF2USpGmgWHdMJKAo3yHvAXxJbXVLxMbUPlhUks6QUknlaQdwhoZJ6quvo5NQGabH9prH5pXxUc2kx-g8rSkWDncDhSLi6R2REkUeQpeQmU81VzwUKpMZgDiEHnGKQ8c8gpUb43HsDdKcMyWgxN-8MNzyG6jmVdvf2WhDnnZToO3wiOoNNfFytKAUXARxw55VCly-1fAHKJ_3nVItKbia2tZn8mnE1sRHbOKYxDQk83rekF2wGcko-PTk6fklrVDj4E97pLtcrHSzwBelvK5tWNKzq_bcfwBNfOOlQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cohort+profile%3A+COBLAnCE%3A+a+French+prospective+cohort+to+study+prognostic+and+predictive+factors+in+bladder+cancer+and+to+generate+real-world+data+on+treatment+patterns%2C+resource+use+and+quality+of+life&rft.jtitle=BMJ+open&rft.au=Lebret%2C+Thierry&rft.au=Bonastre%2C+Julia&rft.au=Fraslin%2C+Ald%C3%A9ric&rft.au=Neuzillet%2C+Yann&rft.series=Cohort+profile&rft.date=2023-12-20&rft.pub=BMJ+Publishing+Group&rft.eissn=2044-6055&rft.volume=13&rft.issue=12&rft_id=info:doi/10.1136%2Fbmjopen-2023-075942&rft_id=info%3Apmid%2F38128940&rft.externalDocID=PMC10749008 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2044-6055&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2044-6055&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2044-6055&client=summon |